Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

BOSTON, Nov. 20 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, has appointed Dr. Victor Kiri, formerly with GlaxoSmithKline, as Director of Pharmacoepidemiology within the Company's Clinical Research Services business. Dr. Kiri's responsibilities include advising clients in the design and conduct of comparative observational studies, offering epidemiological analysis for compounds in development, and guiding strategic decisions regarding future areas of research and product development.

"Regulatory pressures are increasing client demand for pharmacoepidemiological assessments and related studies as part of late phase clinical development," said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL International. "One of PAREXEL's strengths is our late phase development service offering that we call Peri-Approval Clinical Excellence or PACE. Dr. Kiri's in-depth experience in late phase study design and safety-related issues further expands our capabilities to provide clients with integrated pharmacoepidemiology and pharmacovigilance solutions."

"PAREXEL's PACE group has successfully implemented some of the largest and most complex trials of marketed products ever conducted, and I am pleased to be joining such a premier team of global experts," said Dr. Victor Kiri. "I look forward to contributing to PAREXEL's focused expertise in the area of pharmacoepidemiology, and working with clients to determine the right methods and approaches for their late phase studies."

Prior to joining PAREXEL, Dr. Kiri managed epidemiology research at GlaxoSmithKline. He previously served
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswi...day announced that on November 5, 2009, it receive...aq") stating that the Nasdaq Hearing Panel has gra...e NASDAQ Global Market subject to the condition th...ber 31, 2009, the proposed merger (the "Merger") c...
(Date:11/9/2009)..., HOPKINTON, Mass., Nov. 9 /PRNewswire-FirstCal..., a leading provider of tools and services for dru...unced that its Caliper Discovery Alliances and Ser...ommitment for $1.8 million under its contract with... EPA,s ToxCast screening program. This new task o...
(Date:11/7/2009)..., MIAMI BEACH, Fla., Nov. 7 Mos...rodromal symptoms that signal an oncoming HAE atta... treatment and decrease the morbidity associated w...ented today at the 2009 American College of Allerg... Early recognition of symptoms such as fatigue and...
Breaking Medicine Technology:Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3Ikaria Receives Award for Excellence by New Jersey Business 26amp 3B Industry Association 5642 1Ikaria Receives Award for Excellence by New Jersey Business 26amp 3B Industry Association 5642 2Laureate Pharma Announces Signing New Biopharmaceutical Development 26amp 3B Manufacturing Agreement 5637 1Laureate Pharma Announces Signing New Biopharmaceutical Development 26amp 3B Manufacturing Agreement 5637 2Studies improve knowledge of underlying brain changes caused by addiction 10457 1Studies improve knowledge of underlying brain changes caused by addiction 10457 2
...,inhibitor (FASi) compounds, led by FAS031, have d...ograft cell line tested, in both orthotopic,and fl...1975; LX7); two,ovarian; breast; and, colon. In ma...compounds have been shown in extensive preclinical...e. One compound was safely given to,mice twice a d...
...(R) in Patients with Chronic ...vudine,s Sustained Virologic Response Rate for ...J., Oct. 1 Pharmasset, Inc.,(Nasdaq: VRUS ) has ...trials,of clevudine for the treatment of chronic h...oral, once-daily pyrimidine nucleoside analog,that...
Other Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 4Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 5
(Date:11/9/2009)... Dr. Mark Sweeney, a cosmetic dentist...est inviting participants to describe why they are... The winner earns a cosmetic smile makeover worth ...on Austin Dental Spa’s website as well as Yo...cus) November 9, 2009 -- A prominent Austin cosme...
(Date:11/9/2009)... NBC’s Today Show featured a ret... Jill Waibel on Friday Nov. 6th 2009, The segment...fter their first appearance on the Today Show on M...t Lauer regarding their treatments by Dr. Jill Wai...talFX laser. , (PRWEB) No...
(Date:11/9/2009)... The insurance industry has an average...tering the life and health insurance industry fail...Disability Insurance Brokerage has a 4-year retent...for hiring insurance agents. Last year Anthony Del...ational DI Society,s Founders Award for excellence...
(Date:11/9/2009)...ONIO, Nov. 9 In the wak...suing a call to action to all mental health profes...ork. ,, Give an Hour(TM) is a national nonprofi... mental health services to active duty service mem...rces, and veterans of Iraq and Afghanistan who hav...
(Date:11/9/2009)...AUSEN, Switzerland, Nov. 9 /PRNewswire-FirstCall/ ...nvestors and the general public to listen to a web... of Tyco Safety Products and Ed Arditte, Tyco,s Se...ions at the Citi Industrial Manufacturing & Tr... at 1:30 pm EST. The live webcast and supporting m...
Breaking Medicine News(10 mins):Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 2Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 2Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 4Health News:Guardian Disability Insurance Brokerage Establishes The Best Way To Start New Agents 2Health News:Give an Hour(TM) Partners with American Red Cross and Calls All Mental Health Professionals in Texas to Volunteer Their Services 2
...f brain enlargement has been discovered by magneti...ildren who suffer from autism, when in comparison ...s of General Psychiatry//. Abnormalities in ...ion is yet to discovered. The study was conducted ...
...been an increasing tendency by citizens of Scotlan... healthy trend were to continue, it would mean a l...ose a public ban on smoking the following year. ...g compared to the figures in 2003 where merely 40,...
...gular exercise can keep Alzheimer’s disease at bay... Exercise flushes out the toxic chemical that caus...lderly // population. Exercise replaces the toxic...d that exercise doubles the presence of the protei...
...r the first time in 90 years the timings for the l...itional 11PM to round the clock drinking. Thousa...e news with an extra drink in pubs and bars after ... of increased alcohol-induced violence on the stre...
... It's a gastronomic tour-de-force, a caravan that'... traveling to Kolkata and Mumbai to showcase the v...ure and craftsmanship - a true Feast Of The East. ...of the food festival that is under way at the ITC ...
...ton it was reported that hormone injections (Lepti...he weight loss rather than losing weight. The ... Columbia University College of Physicians and Sur...ore difficult is to maintain the weight. A ...
Other Medicine News:Health News:Exercise keeps ‘Alzheimer’s Awa 2Health News:Feast Of The East a gastronomic tour-de-force 2Health News:Leptin Injections Maintain Loss In Body Weight 2
DELFIA Platewash
8 Channel ImmunoWasher
...signed to meet the working and budgetary laborator...user to run set assays at the touch of a button. T...to wash 8 or 12 wells at a time. Reliable, compact...rfill protection, quiet operation, and minimal mai...
SkanWasher 300 (110V)
Medicine Products: